Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Fruquintinib Combined With Chemotherapy vs Bevacizumab Combined With Chemotherapy as Second-line Treatment in Patients With Metastatic Colorectal Cancer: A Prospective, Multi-center, Randomized Study

NCT05555901 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT05555901
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05555901 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Fruquintinib Combined With Chemotherapy vs Bevacizumab Combined With Chemotherapy as Second-line Treatment in Patients With Metastatic Colorectal Cancer: A Prospective, Multi-center, Randomized Study
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Unknown status
Start date
June 18, 2023
Completion date
September 30, 2025
Enrollment
116 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer